Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — Merger or Acquisition (February 2021)
21 slides from Jazz Pharmaceuticals's merger presentation, Feb 4, 2021
Slide 1: Jazz to acquire GW Pharmaceuticals
Jazz to acquire GW Pharmaceuticals Creating an INNOVATIVE, High-Growth, Global Biopharma LEADER February 3, 2021 Exhibit 99.1
Slide 2: Forward-Looking Statements Safe Harbor Statement
Forward-Looking Statements “Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995 This communication contains forward-looking statements regarding Jazz Pharmaceuticals and GW Pharmaceuticals, including, but not limited to, statements related to the proposed acquisition of
Slide 3: Additional Information and Participants in the Solicitation
In connection with the proposed transaction, GW Pharmaceuticals intends to file a proxy statement with the SEC. Each of Jazz Pharmaceuticals and GW Pharmaceuticals may also file other relevant documents with the SEC regarding the proposed transaction. The definitive proxy statement (if and when avai
Slide 4: Creating an Innovative, High-Growth, Global Biopharma Leader
Creating an Innovative, High-Growth, Global Biopharma Leader Three High-Growth Commercial Franchises One Patient-Centric Mission Leadership in Sleep Disorders NEUROSCIENCE Leadership in Epilepsies NEUROSCIENCE Rapidly-Growing Oncology Business ONCOLOGY February 2021
Slide 5: Patient-Centric Innovation Drives our High-Growth Strategy
Patient-Centric Innovation Drives our High-Growth Strategy NEUROSCIENCE & ONCOLOGY Focus on patients with high unmet needs Target addressable physician audiences for efficient commercialization Identify and develop durable, long-lived, differentiated assets Leverage our integrated capabilities and g
Slide 6: Transactions, commercial launches and pipeline progress
TRANSACTIONS PharmaMar U.S. and Canadian rights to Zepzelca (lurbinectedin) SpringWorks Acquired FAAH inhibitor (JZP-150) Redx Pharma Collaboration on two cancer targets Ras/Raf/MAP kinase pathway COMMERCIAL Execute up to five key product launches through 2020 and 2021 Launched in 2020 Xywav (EDS or
Slide 7: Robust Operational and Financial Performance
1 2016 to 2019 audited; 2 G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of November 2, 2020. The company expects that, for the year ended December 31, 2020, reported net revenues and total revenues will meet the guidance range provided on November 2, 2020. Jazz Pharmaceuticals
Slide 8: GW Acquisition Expected to Drive Substantial Shareholder Value
GW Acquisition Expected to Drive Substantial Shareholder Value Creates an innovative, global, high-growth biopharma leader with a robust pipeline and one patient-centric mission Epidiolex has near-term blockbuster potential Combined Neuroscience business has global commercial and operational footpri
Slide 9: Combination Creates Global Neuroscience Leader
Combination Creates Global Neuroscience Leader EPILEPSIES #1 Sleep Disorders Franchise Unparalleled Leader in Cannabinoid Science SLEEP DISORDERS ONCOLOGY Global leaders in complementary areas Addition of third high-growth commercial franchise with blockbuster potential Highly complementary commerci
Slide 10: Epidiolex: A Transformative Treatment in Childhood-Onset Epilepsy
Epidiolex: A Transformative Treatment in Childhood-Onset Epilepsy Pioneering Cannabinoid Therapeutics First and only FDA-approved prescription plant-derived cannabinoid Approved in U.S., EU and Australia Serves Treatment-Resistant Populations with High Unmet Need Approved to treat seizures associate
Slide 11: Epidiolex: Near-Term Blockbuster Potential
Epidiolex: Near-Term Blockbuster Potential Highly Successful Launch Marked by Rapid Adoption in Multiple Major Geographies 2019 SALES $296 2020 SALES1 ~$510 Epidiolex WW Sales ($m) Substantial Value Transforming Patient Lives Robust Pipeline Third High-Growth Franchise Neuroscience Leader February 2
Slide 12: Opportunity to Address Further Significant Unmet Needs
Opportunity to Address Further Significant Unmet Needs ~30-50K Lennox-Gastaut Syndrome ~40-50K Tuberous sclerosis complex ~160K Treatment-resistant childhood-onset epilepsy patients1 ~1M Treatment resistant epilepsy1 seizures persisting despite multiple anti-epileptic drugs (AEDs) ~10K Dravet Syndro
Slide 13: Nabiximols: Next U.S. Commercial Opportunity
Nabiximols: Next U.S. Commercial Opportunity Derived from the whole cannabis plant containing a clinically proven, balanced dose of THC and CBD along with other cannabinoid and non-cannabinoid plant components Approved in >25 countries outside the U.S. as Sativex® for the treatment of spasticity due
Slide 14: GW's Unparalleled Cannabinoid Leadership and Expertise
GW’s Unparalleled Cannabinoid Leadership and Expertise Drives Robust, Innovative Pipeline and Proprietary Growth Engine Enhanced pharmaceutical properties Increased potency Growing IP portfolio Preserving cannabinoid efficacy and safety characteristics Highly-purified botanicals Complex botanicals N
Slide 15: Robust, Innovative Pro Forma Research and Development Pipeline
Robust, Innovative Pro Forma Research and Development Pipeline 1 Opt-in opportunity. 2 Partnered collaboration. 3 Jazz & MD Anderson Cancer Center collaboration study. 4 Planned. 5 Cooperative group study. Neuroscience Oncology Cannabinoids PRE-CLINICAL CombiPlex Exploratory activities JZP-341 (Long
Slide 16: Disciplined Allocation of Capital in Alignment With Strategic Priorities
1 Jazz unaudited cash and investments at December 31, 2020. 2 Assumes aggregate consideration of $7.2B including $6.5B in cash, financed by cash on hand and new debt, and $0.7B in Jazz shares. 3 By the end of 2022 Leveraging financial strength Transaction Aligned to capital allocation strategy DISCI
Slide 17: Accelerates Growth and Enhances Diversification
Accelerates Growth and Enhances Diversification Immediate, Enhanced Diversification Revenue contribution Accelerated, Double-Digit Top Line Revenue Growth Products Acquired or Launched Since 2019 Contribute >65% of Revenue in 2022 1 Represents mid-point of Jazz 2020 Guidance + GW 2020 revenue. GW re
Slide 18: Transaction Summary: Purchase Price, Financial Impact, Funding
Purchase Price Holders of GW ADSs, which each represent 12 GW ordinary shares, will be entitled to receive $220 for each GW ADS Representing $200 in cash and $20 in shares of Jazz stock, subject to a 10% collar centered on Jazz’s closing share price on February 1, 2021 Total transaction enterprise v
Slide 19: Shared Commitment to Innovating to Transform Patient Lives
Shared Commitment to Innovating to Transform Patient Lives Life-Changing Medicines. Redefining Possibilities. Shared Culture and Exceptional Talent Will Advance our Mission to Transform the Lives of Patients The only low-sodium oxybate for cataplexy or EDS in narcolepsy Sara Narcolepsy Patient1 Nove
Slide 20: Adds a Third High-Growth Commercial Franchise to Jazz Portfolio
February 2021 Adds a Third High-Growth Commercial Franchise to Jazz Portfolio Expands growing Neuroscience business with Epidiolex, a global, high-growth childhood-onset epilepsy franchise with near-term blockbuster potential Enhances product diversification through the addition of a third high-grow
Slide 21: Q&A
Q&A é Jazz Pharmaceuticals
Jazz Pharmaceuticals — Merger or Acquisition (February 2021) on 6ix